India, Nov. 20 -- image credit- shutterstock

Actimed Therapeutics, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has entered into a licensing agreement with Mankind Pharma, one of India's leading innovative pharmaceutical companies and a shareholder in Actimed, granting Mankind exclusive rights to develop and commercialise Actimed's products for use in the treatment and/or prevention of cachexia in India and South Asian territories.

Under the agreement, Mankind gains exclusive territorial product rights in the Indian subcontinent, comprising India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar. The license covers Actime...